RightFit Trial Directory

Parkinson's Disease clinical trials in New York, NY

38 recruiting parkinson's disease studies with a site in New York, NY.

All trials in New York, NY · All Parkinson's Disease trials

RecruitingPhase 3NCT06623422

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Sponsor: Merck Sharp & Dohme LLC

Buffalo, NY · East Syracuse, NY · New York, NY · +51 more sites

RecruitingPhase 3NCT06312176

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Sponsor: Merck Sharp & Dohme LLC

Brooklyn, NY · Mineola, NY · New York, NY · +43 more sites

RecruitingPhase 3NCT06841354

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Sponsor: Merck Sharp & Dohme LLC

Mineola, NY · New York, NY · +37 more sites

RecruitingPhase 3NCT06952504

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Sponsor: Merck Sharp & Dohme LLC

Mineola, NY · New York, NY · +50 more sites

RecruitingPhase 3NCT06989112

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Sponsor: AstraZeneca

New York, NY · +60 more sites

RecruitingPhase 3NCT07216703

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Sponsor: Merck Sharp & Dohme LLC

Mineola, NY · New York, NY · +28 more sites

RecruitingPhase 2NCT05700825

Rehabilitation of Airway Protection in Parkinson's Disease

Sponsor: Teachers College, Columbia University

New York, NY · +1 more sites

RecruitingPhase 2NCT06996652

An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)

Sponsor: Yale University

New York, NY · +17 more sites

RecruitingPhase 1 / Phase 2NCT05319730

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Sponsor: Merck Sharp & Dohme LLC

East Syracuse, NY · New York, NY · +3 more sites

RecruitingPhase 1 / Phase 2NCT06469944

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

Sponsor: Merck Sharp & Dohme LLC

East Syracuse, NY · New York, NY · +6 more sites

RecruitingPhase 3NCT07174310

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Sponsor: Hoffmann-La Roche

Amherst, NY · Commack, NY · New York, NY · +50 more sites

RecruitingPhase 2NCT07432958

A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

Sponsor: Appello Pharmaceuticals, Inc.

New York, NY · +28 more sites

RecruitingPhase 2NCT06680830

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Sponsor: Neuron23 Inc.

Manhasset, NY · New York, NY · +42 more sites

RecruitingPhase not listedNCT07849413

Visual Hallucinations in Lewy Body Diseases

Sponsor: NYU Langone Health

New York, NY

RecruitingPhase 2 / Phase 3NCT06976268

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

Sponsor: Biohaven Therapeutics Ltd.

Albany, NY · New York, NY · +22 more sites

RecruitingPhase not listedNCT07567794

GBPDC: Gut-Brain in PD Consortium Master Protocol

Sponsor: Duke University

New York, NY · +6 more sites

RecruitingPhase 2NCT07005180

Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

Sponsor: Hillhurst Biopharmaceuticals, Inc.

New York, NY · +7 more sites

RecruitingPhase 2 / Phase 3NCT07284784

A Study of Buntanetap in Participants With PD

Sponsor: Annovis Bio Inc.

New York, NY · +26 more sites

RecruitingPhase 2NCT07002034

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

Sponsor: Reunion Neuroscience Inc

Buffalo, NY · New York, NY · +30 more sites

RecruitingPhase 2NCT07804615

A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy

Sponsor: Vima Therapeutics

Amherst, NY · New York, NY · Patchogue, NY · +26 more sites

RecruitingPhase not listedNCT04994015

Parkinson's Foundation PD GENEration Genetic Registry

Sponsor: Parkinson's Foundation

New York, NY · +60 more sites

RecruitingPhase not listedNCT07330258

A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications

Sponsor: Bayer

New York, NY · Stony Brook, NY · Williamsville, NY · +24 more sites

RecruitingPhase 1 / Phase 2NCT06445972

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

Sponsor: Merck Sharp & Dohme LLC

East Syracuse, NY · New York, NY · +6 more sites

RecruitingPhase 1 / Phase 2NCT04165070

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

Sponsor: Merck Sharp & Dohme LLC

New York, NY · +17 more sites

RecruitingPhase not listedNCT04165798

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

Sponsor: Merck Sharp & Dohme LLC

New York, NY · +17 more sites

RecruitingPhase not listedNCT07752355

Young Onset Parkinson's Disease Subtypes and Pathogenic Mechanisms

Sponsor: NYU Langone Health

New York, NY

RecruitingPhase not listedNCT04239079

Autoimmune Features of Neurodegenerative Disorders

Sponsor: Columbia University

New York, NY

RecruitingPhase 3NCT06944522

A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

Sponsor: BlueRock Therapeutics

Buffalo, NY · New York, NY · +31 more sites

RecruitingNot applicableNCT07207122

Effects of Transcranial Focused Ultrasound Stimulation (tFUS) on Neurological and Cognitive Outcomes in Parkinson's Disease

Sponsor: Sanmai Technologies PBC dba Sanmai

New York, NY · +3 more sites

RecruitingPhase not listedNCT04477785

PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

Sponsor: Michael J. Fox Foundation for Parkinson's Research

New York, NY · Rochester, NY · +27 more sites

RecruitingPhase not listedNCT01799915

Natural History Study of Synucleinopathies

Sponsor: NYU Langone Health

New York, NY · +4 more sites

RecruitingPhase not listedNCT05347407

Parkinson's Disease Biomarkers in Nerve Cells in the Gut

Sponsor: Weill Medical College of Cornell University

New York, NY

RecruitingPhase 1 / Phase 2NCT07102342

This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.

Sponsor: iRegene Therapeutics Co., Ltd.

New York, NY

RecruitingPhase not listedNCT04991831

A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease

Sponsor: InSightec

New York, NY · +6 more sites

RecruitingPhase not listedNCT05539196

A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications

Sponsor: InSightec

New York, NY · +3 more sites

RecruitingPhase 1 / Phase 2NCT06753331

A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease

Sponsor: Sumitomo Pharma America, Inc.

New York, NY · +1 more sites

RecruitingPhase not listedNCT06203106

NYSCF Scientific Discovery Biobank

Sponsor: New York Stem Cell Foundation Research Institute

New York, NY

RecruitingEarly Phase 1NCT06540989

Noise-augmented Automatic Speech Recognition for Speech Treatment in Parkinson's Disease

Sponsor: Teachers College, Columbia University

New York, NY

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.